Study of Smith-Lemli-Opitz Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001721|
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : December 17, 2018
Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder (autosomal recessive) caused by an abnormality in the production of cholesterol. The disorder can occur in both a "mild" or "severe" form. SLOS is associated with multiple birth defects and mental retardation. Some of the birth defects include; abnormal facial features, poor muscle tone, poor growth, shortened life span, and abnormalities of the heart, lungs, brain, gastrointestinal tract, limbs, genitalia, and kidneys.
There is no known cure for SLOS but recently patients have been treated with increased amounts of cholesterol in their diet. The cholesterol in a persons diet is unable to correct the abnormalities in the patient's organs, but researchers hope it will improve growth failure and mental retardation.
This study was developed to answer questions about the causes and complications of SLOS, as well as the effectiveness of cholesterol treatment. The study will enroll patients diagnosed with SLOS, and their mothers. The objectives of the study will be to address the following questions:
- <TAB> What is the prognosis / natural history of the demyelination in the nervous system of patients with SLOS?
- <TAB> Do patients with SLOS have other problems concerning the function of their endocrine systems?
- <TAB>What are the genetic make-ups of patients with SLOS?
- <TAB>Can further studies of cholesterol metabolism and genetic testing, using SLOS fibroblasts, increase the understanding of SLOS?<TAB>...
|Condition or disease|
|Abnormalities Inborn Errors of Metabolism Mental Retardation Muscle Hypotonia Smith Lemli Opitz Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome|
|Study Start Date :||March 23, 1998|
Patients diagnosed with SLOS
- biochemical biomarkers [ Time Frame: at every visit ]analyzing multiple tissues for cholesterol precursors and secondary analyses that correlate with disease severity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001721
|Contact: Margarita J Raygada, Ph.D.||(301) email@example.com|
|Contact: Forbes D Porter, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Forbes D Porter, M.D.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|